* Anavex Life Sciences Corp AVXL.OQ AVXL.O is expected
to show
no change in quarterly revenue when it reports results for the
period ending June 30 2023
*
* LSEG's mean analyst estimate for Anavex Life Sciences
Corp is
for a loss of 15 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Anavex Life
Sciences Corp is $47.00, above its last closing price
of $6.70.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2023 -0.17 -0.17 -0.14 Beat 16
Mar. 31 2023 -0.19 -0.19 -0.17 Beat 8.9
Dec. 31 2022 -0.20 -0.19 -0.17 Beat 10.5
Sep. 30 2022 -0.16 -0.16 -0.18 Missed -11.1
Jun. -0.15 -0.15 -0.16 Missed -5.3
30 2022
Mar. 31 2022 -0.17 -0.17 -0.14 Beat 16.4
Dec. 31 2021 -0.15 -0.15 -0.14 Beat 9.7
Sep. 30 2021 -0.16 -0.15 -0.15 Met -2.3
This summary was machine generated November 24 at 13:50 GMT.
All figures in US dollars unless otherwise stated